Claims
- 1. A method of modifying an isolated wild type BVD viral genome for use in a vaccine, comprising mutating the genomic nucleic acid of an isolated wild type virus to inactivate the Npro protease gene.
- 2. The method of claim 1, wherein the inactivation of said Npro protease gene is accomplished by a procedure comprising:(a) reverse transcribing the genomic RNA from the wild type BVD virus to form cDNA; (b) cloning the cDNA of step (a); and (c) mutating the Npro protease gene in the cloned cDNA of step (b) so that the mutated gene produces a gene product having a reduced rate of function.
- 3. The method of claim 2, wherein said Npro protease gene is inactivated by deleting all or part of its sequence from said wild type BVD viral genome.
- 4. A method of attenuating a wild type BVD virus for use in a vaccine, comprising mutating the genomic nucleic acid of said virus to inactivate the Npro protease gene, wherein attenuation is accomplished by a procedure comprising:(a) isolating said wild type BVD virus; (b) cloning the genomic nucleic acid of the isolated virus of step (a); (c) mutating the cloned genomic nucleic acid of step (b) so as to inactivate the Npro protease gene; and (d) transforming or transfecting the mutated nucleic acid of step (c) into a host cell to produce attenuated virus.
- 5. The method of claim 4, wherein said Npro protease gene is inactivated by deleting all or part of its sequence from the wild type BVD viral genome.
Parent Case Info
This application claims priority from U.S. provisional application Ser. No. 60/107,908, which was filed on Nov. 10, 1998.
Non-Patent Literature Citations (1)
Entry |
Behrens, et al. Journal of Virology. vol. 72, No. 3, pp. 2364-2372, Mar. 1998.* |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/107908 |
Nov 1998 |
US |